<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>High-dose furmonertinib &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/high-dose-furmonertinib/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 11:56:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>High-dose furmonertinib &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>High-Dose Furmonertinib Targets EGFR Exon 20 Insertions</title>
		<link>https://bioengineer.org/high-dose-furmonertinib-targets-egfr-exon-20-insertions/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 20 May 2025 13:03:40 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[EGFR exon 20 insertions]]></category>
		<category><![CDATA[High-dose furmonertinib]]></category>
		<category><![CDATA[Lung adenocarcinoma treatment]]></category>
		<category><![CDATA[Real-world study]]></category>
		<category><![CDATA[tyrosine kinase inhibitors]]></category>
		<guid isPermaLink="false">https://bioengineer.org/high-dose-furmonertinib-targets-egfr-exon-20-insertions/</guid>

					<description><![CDATA[In the ever-evolving landscape of lung cancer research, a recent real-world study published in BMC Cancer shines new light on a particularly challenging subtype: lung adenocarcinoma (LUAD) harboring EGFR exon 20 insertion mutations (ex20ins). Unlike the more common and well-studied EGFR mutations such as exon 19 deletions or L858R point mutations, which have established targeted [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">245891</post-id>	</item>
	</channel>
</rss>
